Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clemens Kratochwil

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 13, 2023
Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET-but not its lymph-node metastasis and primary-tumorErik Winter, Stefanie Zschäbitz, Clemens Kratochwil
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 29, 2020
Internal Radiation TherapyUwe Haberkorn, Clemens Kratochwil, Frederik Giesel
Seminars in Nuclear Medicine|March 17, 2020
<sup>225</sup>Ac-PSMA-617 for Therapy of Prostate CancerClemens Kratochwil, Uwe Haberkorn, Frederik Lars Giesel
Seminars in Nuclear Medicine|June 23, 2019
Radionuclide Therapy of Metastatic Prostate CancerClemens Kratochwil, Uwe Haberkorn, Frederik L Giesel
Urology Case Reports|May 23, 2024
A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancerAndreas Tulipan, Clemens Kratochwil, Jacob Lilleby, et al.
Current Opinion in Chemical Biology|May 18, 2021
Ligand engineering for theranostic applicationsAnnette Altmann, Clemens Kratochwil, Frederik Giesel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2017
The Future of Radioligand Therapy: α, β, or Both?Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2024
1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?Uwe Haberkorn, Annette Altmann, Frederik L Giesel, et al.
PET Clinics|April 8, 2023
Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical TranslationYuriko Mori, Clemens Kratochwil, Uwe Haberkorn, et al.
Cancers|November 27, 2021
Radioligands Targeting Fibroblast Activation Protein (FAP)Thomas Lindner, Frederik L Giesel, Clemens Kratochwil, et al.
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
European Journal of Nuclear Medicine and Molecular Imaging|February 13, 2023
Liver metastasis of a neuroendocrine tumor demonstrates intense uptake in PSMA-PET-but not its lymph-node metastasis and primary-tumorErik Winter, Stefanie Zschäbitz, Clemens Kratochwil
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|June 29, 2020
Internal Radiation TherapyUwe Haberkorn, Clemens Kratochwil, Frederik Giesel
Seminars in Nuclear Medicine|March 17, 2020
<sup>225</sup>Ac-PSMA-617 for Therapy of Prostate CancerClemens Kratochwil, Uwe Haberkorn, Frederik Lars Giesel
Seminars in Nuclear Medicine|June 23, 2019
Radionuclide Therapy of Metastatic Prostate CancerClemens Kratochwil, Uwe Haberkorn, Frederik L Giesel
Urology Case Reports|May 23, 2024
A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancerAndreas Tulipan, Clemens Kratochwil, Jacob Lilleby, et al.
Current Opinion in Chemical Biology|May 18, 2021
Ligand engineering for theranostic applicationsAnnette Altmann, Clemens Kratochwil, Frederik Giesel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2017
The Future of Radioligand Therapy: α, β, or Both?Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2024
1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?Uwe Haberkorn, Annette Altmann, Frederik L Giesel, et al.
PET Clinics|April 8, 2023
Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical TranslationYuriko Mori, Clemens Kratochwil, Uwe Haberkorn, et al.
Cancers|November 27, 2021
Radioligands Targeting Fibroblast Activation Protein (FAP)Thomas Lindner, Frederik L Giesel, Clemens Kratochwil, et al.
Pageof 17